Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/132010
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAlcover García, Juan-
dc.contributor.authorFilella Pla, Xavier-
dc.contributor.authorLuque Gálvez, Ma. Pilar-
dc.contributor.authorMolina, Rafael (Molina Porto)-
dc.contributor.authorIzquierdo Reyes, Laura-
dc.contributor.authorAugé Fradera, Josep Maria-
dc.contributor.authorAlcaraz Asensio, Antonio-
dc.date.accessioned2019-04-10T18:10:16Z-
dc.date.available2019-04-10T18:10:16Z-
dc.date.issued2010-10-
dc.identifier.issn0250-7005-
dc.identifier.urihttp://hdl.handle.net/2445/132010-
dc.description.abstractAIM: The usefulness of interleukin 6 (IL-6) and its soluble receptor IL-6sR in the prediction of the biochemical recurrence was evaluated in patients with prostate cancer treated with radical prostatectomy. PATIENTS AND METHODS: IL-6 and sIL-6R serum levels were measured in 96 patients with prostate cancer. RESULTS: Using the log-rank test, it was evident that patients with preoperative serum levels of IL-6 higher than 1.2 pg/ml had a significantly increased probability of biochemical recurrence (p=0.031). We also observed that the Gleason score was associated with the risk of progression (p=0.033), but no relation was observed with TNM classification, PSA, % free PSA or sIL-6R. In a multivariate analysis, only IL-6 serum levels remained as a predictor of biochemical recurrence (p=0.040). CONCLUSION: The results presented here demonstrated the usefulness of IL-6 in predicting the biochemical progression of prostate cancer, pointing towards an association between inflammation and the aggressiveness of the tumor.-
dc.format.extent4 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherInternational Institute of Anticancer Research-
dc.relation.isformatofReproducció del document publicat a: http://ar.iiarjournals.org/content/30/10/4369.long-
dc.relation.ispartofAnticancer Research, 2010, vol. 30, num. 10, p. 4369-4372-
dc.rights(c) International Institute of Anticancer Research, 2010-
dc.sourceArticles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques)-
dc.subject.classificationCàncer de pròstata-
dc.subject.classificationTumors-
dc.subject.classificationMarcadors tumorals-
dc.subject.otherProstate cancer-
dc.subject.otherTumors-
dc.subject.otherTumor markers-
dc.titlePrognostic value of IL-6 in the localized prostatic cancer-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec621775-
dc.date.updated2019-04-10T18:10:16Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid21036766-
Appears in Collections:Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques)

Files in This Item:
File Description SizeFormat 
621775.pdf2.73 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.